Foi realizado um estudo de farmacocinética da polimixina B em pacientes críticos com desenvolvimento de um modelo populacional. Os critérios de inclusão foram pacientes internados em Unidade de Terapia Intensiva, com idade igual ou superior a 18 anos e em uso de polimixina B intravenosa por um período mínimo de 48 horas. Amostras de sangue, urina e dialisato foram coletadas durante um intervalo de doses no estado de equilíbrio. A concentração de polimixina B no plasma foi medida por meio de cromatografia líquida de alta performance associada à espectrometria de massas acoplada à espectrometria de massas, sua ligação às proteínas plasmáticas foi determinada por meio de diálise de equilíbrio rápido e a fração livre foi calculada. Foram realizadas análise farmacocinética populacional e Simulações de Monte Carlo. Foram incluídos 24 pacientes, dos quais dois estavam em hemodiálise contínua; 54,2% eram do sexo masculino e as medianas da idade, do escore APACHE e do peso corporal total foram de 61,5 anos, 21,5 e 62,5kg, respectivamente. As doses de polimixina B, conforme prescrição do médico assistente, variaram entre 0,45-3,38mg/kg/dia. O clearance estimado da creatinina nos 22 pacientes sem hemodiálise variou entre 10-143mL/min. A mediana da fração livre plasmática da polimixina B foi de 0,42 e a média (± desvio padrão) da fração livre da área sob a curva ao longo de um dia (fAUC0-24h) da polimixina B foi de 29,2±12,0mg•h/L, incluindo os pacientes em hemodiálise. A polimixina B foi excretada predominantemente por vias não renais e as medianas de sua recuperação urinária de forma inalterada foi de 4,04% e do seu clearance renal foi de 0,061L/hora. Nos pacientes 1 e 2 em hemodiálise foram identificados, respectivamente, clearance corporal total de 0,043 e 0,027L/h/kg, clearance da hemodiálise de 0,0052 e 0,0015L/h/kg; no dialisato foram recuperados 12,2% e 5,62% da dose como polimixina B não modificada. O clearance corporal total da polimixina B não mostrou nenhuma relação com o clearance da creatinina, escore APACHE II ou idade. A disposição da polimixina B no tempo foi adequadamente descrita pelo modelo de dois compartimentos com eliminação linear. O modelo farmacocinético populacional proporcionou ajustes excelentes para os perfis observados de concentração-tempo para pacientes individuais e as concentrações individuais e populacionais ajustadas foram precisas. O ajuste dos clearances e dos volumes de distribuição para o peso corporal total reduziu a variabilidade intersujeitos em 3,4% para o clearance e 41,7% para o volume de distribuição central; nos pacientes em diálise, após esse ajuste, os parâmetros estimados se assemelharam aos dos demais pacientes. As Simulações de Monte Carlo foram feitas com seis diferentes regimes de doses clinicamente relevantes escalonados pelo peso corporal total. O regime de doses de 1,5mg/kg 12/12h forneceu uma AUC0-24h de polimixina B no dia 4 de 90.4mg•hora/L para 50% dos pacientes, adequada para erradicação bacteriana em infecções graves por Pseudomonas aeruginosa ou Acinetobacter baumannii com concentração inibitória mínima para a polimixina B ≤2mg/L. Nas Simulações de Monte Carlo também foi possível identificar que uma melhor área sob a curva só foi atingida no dia 4 de tratamento. Este estudo mostrou que a dose de polimixina B intravenosa deve ser ajustada ao peso corporal total, que o melhor regime de doses é o de 1,5mg/kg 12/12h precedido de dose de ataque de 2,5mg/kg e que não há indicação de ajuste para a função renal, mesmo em pacientes em hemodiálise contínua. / A polymyxin B pharmacokinetics study in critically ill patients was conducted with the development of a population modeling. The inclusion criteria were patients from Intensive Care Unit, aged ≥18 years who received intravenous polymyxin B for ≥ 48 hours. Blood, urine and dialysate samples were collected over a dosing interval at steady state. Polymyxin B concentrations was measured by liquid chromatography- tandem mass spectrometry, its plasma protein binding was determined by rapid equilibrium dialysis and unbound fraction was calculated. Population pharmacokinetic analysis and Monte Carlo Simulations were conducted. Twenty four patients were enrolled, two of whom on continuous hemodialysis; 54.2% were male; the median of age, APACHE II score and total body weight were 61.5years, 21.5 and 62.5kg, respectively. The physician-selected dose of polymyxin B was 0.45- 3.38mg/kg/day. The creatinine clearance of the 22 patients without hemodialysis ranged from 10 to 143mL/min. The median unbound fraction in plasma of polymyxin B was 0.42 and the mean (± standard deviation) of the area under the curve over a day for unbound (fAUC0-24h) polymyxin B was 29.2±12.0mg•hour/L, including hemodialysis patients. Polymyxin B was predominantly nonrenally cleared with median unchanged urinary recovered of 4.04%; the median renal clearance was 0.061L/hour. Patients 1 and 2 in hemodialysis presented, respectively, total body clearance of 0.043 and 0.027L/h/kg, hemodialysis clearance of 0.0052 and 0.0015L/h/kg; 12.2% and 5.62% of the polymyxin dose were recovered intact in the dialysate. Polymyxin B total body clearance did not show any relationship with creatinine clearance, APACHE II score, or age. The time course of polymyxin B concentrations was well described by a 2-compartment disposition model with linear elimination. The population pharmacokinetics model provided excellent fits to the observed concentration-time profiles for individual patients and the individual-fitted and population-fitted concentrations were adequately precise. Linear scaling of clearances and volumes of distribution by total body weight reduced the between subject variability in 3.4% for clearance and 41.7% for the central volume of distribution; after this scaling, the estimated parameters in hemodialysis patients were within the range of estimates from the other patients. The population mean of the total body clearance of polymyxin B when scaled by total body weight (0.0276L/hour/kg) showed remarkably low interindividual variability. The Monte Carlo Simulations were performed for six different clinically relevant dosage regimens scaled by total body weight. The regimen of 1.5mg/kg/12 hours provided an AUC0- 24h of polymyxin B of 90.4 mg•h/L in day 4 for 50% of patients which is appropriate considering severe infections by Pseudomonas aeruginosa or Acinetobacter baumannii with minimal inhibitory concentration for polymyxin B ≤2mg/L. In Monte Carlo Simulations we also identified that the best area under the curve was attained only in the day 4 of the treatment. This study showed that doses of intravenous polymyxin B are best scaled by total body weight, that the best regimen of doses is 3mg/kg/day with a loading dose of 2.5mg/kg and that its dosage selection should not be based on renal function, even in patients in continuous hemodialysis.

An increasing number of proteins with unknown function have their three-dimensional structure solved at high resolution. This situation, largely due to structural genomics initiatives, has been stimulating the development of automated structure-based function prediction methods. Knowledge of residues important for function – and more particularly – for binding can help automated prediction of function in different ways. The properties of a binding site such as its shape or amino acid composition can provide clues on the ligand that may bind to it. Also, having information on functionally important regions in similar proteins can refine the process of annotation transfer between homologues.<p>Experimental results indicate that functional residues often have an unfavourable contribution to the stability of the folded state of a protein. This observation is the underlying principle of several computational methods for predicting the location of functional sites in protein structures. These methods search protein structures for destabilising residues, with the assumption that these are likely to be important for function.<p>We have developed a method to detect clusters of destabilising residues which are in close spatial proximity within a protein structure. Individual residue contributions to protein stability are evaluated using detailed atomic models and an energy function based on fundamental physico-chemical principles.<p>Our overall aim in this work was to evaluate the overlap between these clusters of destabilising residues and known binding sites in proteins.<p>Unfortunately, reliable benchmark datasets of known binding sites in proteins are sorely lacking. Therefore, we have undertaken a comprehensive approach to define binding sites unambiguously from structural data. We have rigorously identified seven issues which should be considered when constructing datasets of binding sites to validate prediction methods, and we present the construction of two new datasets in which these problems are handled. In this regard, our work constitute a major improvement over previous studies in the field.<p>Our first dataset consists of 70 proteins with binding sites for diverse types of ligands (e.g. nucleic acids, metal ions) and was constructed using all available data, including literature curation. The second dataset contains 192 proteins with binding sites for small ligands and polysaccharides, does not require literature curation, and can therefore be automatically updated.<p>We have used our dataset of 70 proteins to evaluate the overlap between destabilising regions and binding sites (the second dataset of 192 proteins was not used for that evaluation as it constitutes a later improvement). The overlap is on average limited but significantly larger than random. The extent of the overlap varies with the type of bound ligand. Significant overlap is obtained for most polysaccharide- and small ligand-binding sites, whereas no overlap is observed for nucleic acid-binding sites. These differences are rationalised in terms of the geometry and energetics of the binding sites.<p>Although destabilising regions, as detected in this work, can in general not be used to predict all types of binding sites in protein structures, they can provide useful information, particularly on the location of binding sites for polysaccharides and small ligands.<p>In addition, our datasets of binding sites in proteins should help other researchers to derive and validate new function prediction methods. We also hope that the criteria which we use to define binding sites may be useful in setting future standards in other analyses. / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

<p>S. 1-40: sammanfattning, s. 41-96: 5 uppsatser</p> / digitalisering@umu.se

Glucocorticosteroide (GC) spielen für viele endogene Prozesse im Organismus eine wichtige Rolle. Sie regulieren die Gluconeogenese sowie den Lipid- und Proteinstoffwechsel. Außerdem sind sie für die Stressregulierung über die Hypothalamus-Nebennierenrinden-Achse verantwortlich. Therapeutisch kommen die GCs wegen ihrer entzündungshemmenden Wirkung zum Einsatz und werden u.a. bei Asthma und Gelenkentzündungen angewandt. Diese Eigenschaft macht sie auch interessant für den Gebrauch im Sportbereich. Dort wird ihre Anwendung über die Weltantidopingagentur reguliert. Ihr oraler, intramuskulärer, intravenöser und rektaler Gebrauch ist im Wettkampf verboten. Diese Einschränkung bzgl. des Applikationszeitraumes und des Applikationsweges erschwert die diagnostische Aussagekraft von Routinedopingproben, welche im Urin durchgeführt werden. Ein Grenzwert von 30 ng/ml soll einen legalen Gebrauch von einem Missbrauch abgrenzen. Die endogenen Glucocorticosteroide stellen hierbei jedoch einen Graubereich dar. Endogen wird Cortisol in einem zirkadianen Rhythmus produziert und die Produktion ist stressinduziert. Somit kommt es zu ausgeprägten intra- und interindividuellen Streuungen der endogenen Produktion. Dadurch bedingt ist eine Abgrenzung der endogenen Produktion von einer legalen Anwendung bzw. einem Missbrauch im Rahmen der Dopingrichtlinien im Urin nicht möglich. Speziell für den Nachweis von endogenen Substanzen ist es wichtig, eine Methode zu finden, mit der es möglich ist, die endogene Produktion von einer exogenen Bezugsquelle abzugrenzen. Dabei haben sich zwei Wege als hilfreich herausgestellt. Zum einen, wenn die Differenzierung nicht an Hand von Absolutkonzentrationen sondern durch die Anwendung von Analytverhältnissen durchgeführt wird. Zum anderen, wenn zusätzliche Untersuchungen im Speichel oder Haar durchgeführt werden. Haar- und Speichelproben zählen zu den ergänzenden Matrizes der Routineuntersuchungsmedien Urin und Blut und werden bereits in vielen forensischen und klinischen Laboren für diagnostische Fragestellungen verwendet. Diese Matrizes liefern wichtige Hinweise auf den akuten (Speichel) oder chronischen/ zurückliegenden (Haar) Gebrauch bzw. Missbrauch von Medikamenten und Drogen. Sowohl die Haar- als auch Speichelmatrix sollen den physiologisch aktiven Anteil von Substanzen im Blut widerspiegeln und somit korrektere Rückschlüsse auf deren Wirksamkeit zulassen. Das endogene Glucocorticosteroid Cortisol steht seit der Jahrtausendwende im Blickpunkt vieler Forschungen, welche sich mit dessen Bedeutung für die Stressantwort befassen und Cortisol u.a. im Speichel und Haar nachweisen. Auffällig ist dabei, dass die ersten Arbeiten fast ausschließlich mittels immunchemischen Nachweisverfahren erfolgten. Erst in den letzten fünf Jahren wurde vermehrt LC-MS/MS-Verfahren angewandt. Vorteil dieser ist, dass der Nachweis von Substanzen selektiv erfolgt und Kreuzreaktionen nicht stattfinden. Weiterhin ist es vorteilhaft, dass die Konzentrationen von mehreren Analyten mit einer Messung bestimmt werden können. So ist es zum Beispiel möglich Cortisol und andere Steroide, z.B. dem Cortison parallel nachzuweisen. Cortison spielt für die physiologische Wirkung der Glucocorticosteroide im Körper keine Rolle, da es selbst nicht biologisch aktiv ist. Deshalb wurde es in bisherigen Forschungen für diagnostische Aussagen nicht berücksichtigt. Mit Verwendung der LC-MS/MS-Technologie werden jedoch beide endogenen GCs zunehmend nebeneinander bestimmt. Bei der Betrachtung von unterschiedlichen Untersuchungsmedien ist auffällig, dass sich die Konzentrationsverhältnisse Cortisol zu Cortison unterscheiden. Entgegengesetzte Verhält-nisse werden ersichtlich, wenn die GC-Konzentrationen im Blut mit denen im Speichel bzw. Haar verglichen werden. Bisher wurden diese Beobachtungen mit der lokalen Wirksamkeit von Enzymen, welche die Corticosteroide ineinander umwandeln, erklärt. Im Rahmen der vorliegenden Dissertation wurde folgender Fragestellung für die Nachweisbarkeit der Glucocorticosteroide nachgegangen: „Wie hoch ist der Anteil der Plasmaproteinbindung der GCs im Blut und welche Rückschlüsse lassen sich daraus auf die Konzentrationsverschiebung innerhalb der einzelnen Matrizes ziehen?“ Basierend auf die einzelnen Teilprojekte wurden sowohl Plasmaproben als auch Speichel- und Haarproben hinsichtlich ihrer GC-Konzentrationen analysiert. Die Untersuchung von Kontrollproben ermöglichte es, Referenzwerte unter Normalbedingungen zu erheben. Die Ergebnisse aus den Projekten ergaben, dass die beiden endogen GCs Cortisol und Cortison in unterschiedlichen Konzentrationsverhältnissen in den Analysenmedien vorkommen: Plasma: Gesamtkonzentration F:E ca. 3:1 freie Konzentrationen F:E ca. 1:1 Speichel: F:E ca. 1:5 Haar: F:E ca. 1:3 Die Bestimmung der Plasmaproteinbindung (PPB) beider endogener GCs hat gezeigt, dass Cortisol mit ca. 96 % stärker an die Transportproteine CBG und Albumin bindet als Cortison mit ca. 85 %. Dies führt dazu, dass sich die freien, nicht-proteingebundenen Konzentrationen angleichen und es zu einer Verhältnisverschiebung von Cortisol zu Cortison von 3:1 auf 1:1 kommt. Somit stehen vergleichbare Konzentrationen für die Inkorporation ins Haar bzw. die Diffusion in den Speichel zur Verfügung. Es konnte gezeigt werden, dass die freien Plasmakonzentrationen beider GC stark mit den Speichelkonzentrationen korrelieren. Cortisol aber unterproportional und Cortison überproportional vom Plasma in den Speichel übergeht. Dies kann mit zwei weiteren Mechanismen, welche während der Diffusion eine Rolle spielen, der unterschiedlichen Lipophilie und der Inaktivierung durch lokale Enzym-reaktionen, erklärt werden. Weiterhin wurde gezeigt, dass sich die Tagesrhythmik der GC-Produktion im Speichel abbilden lässt und eine starke Korrelation zwischen Cortison und Cortisol vorliegt. Mit Hilfe einer Grenzfunktion können endogene Referenzkonzentrationen definiert und Messdaten eingeordnet werden. Unter anderem wurde gezeigt, dass eine Hormonersatztherapie mit Hydrocortison zu einer Verschiebung der Metabolisierung und der PPB führt und somit ein Gebrauch/Missbrauch von GCs durch abweichende Konzentrationsverhältnisse nachweisbar ist. Speicheluntersuchungen während einer chronischen Stresssituation (Schwangerschaft) zeigen, dass die GC-Produktion stetig ansteigt und sich besonders die morgendlichen Werte unterscheiden. Um die tageszeitlichen und stressbedingten Schwankungen der GC-Produktion auszublenden und eine längere Zeitspanne zu betrachten, wurden zusätzlich Haarproben analysiert. In diesen wurde ein kontinuierlicher Anstieg der GCs in den proximalen Haarsegmenten nachgewiesen, was auf eine kontinuierlich erhöhte Inkorporation während der chronischen Stresssituation schließen lässt. Außerdem wurde gezeigt, dass die Haarkonzentrationen dem Auswascheffekt unterliegen und die nachweisbaren Konzentrationen geringer werden, je älter das Haar wird. Schlussfolgernd kann gesagt werden, dass beide Mechanismen (Einlagerung und Auswaschung) konkurrieren und deshalb Referenzdaten nur für das proximale Segment erhoben werden können. Für weitere Segmente sind die Auswirkungen der individuellen Einflüsse nicht mehr allgemeingültig kalkulierbar und nur noch intraindividuelle Vergleiche nach mehrmaliger Beprobung aussagekräftig. Sind die Effekte der verstärkten Inkorporation größer als die Auswaschung, lassen sich diese auch Monate später erkennen. Zusammenfassend kann gesagt werden, dass die Plasmaproteinbindung der GCs zur Verhältnisverschiebung der Konzentrationen im Blut, Speichel und Haar beiträgt. Etwa 50 % des beobachteten Effekts kann der PPB zugeordnet werden. Weitere Quellen sind die unterschiedliche Lipophilie der GCs und die enzymatische Umwandlung, welche im Rahmen der vorliegenden Arbeit jedoch nicht „quantitativ“ betrachtet wurden. Die enzymatische Inaktivierung wurde bis dato als Hauptverantwortliche für die Konzentrationsverschiebung diskutiert. Mit der aktuellen Arbeit wurde dies widerlegt, und die Plasmaproteinbindung als Hauptquelle identifiziert.

Protein-protein and protein-ligand interactions are fundamental as many proteins mediate their biological function through these interactions. Many important applications follow directly from the identification of residues in the interfaces between protein-protein and protein-ligand interactions, such as drug design, protein mimetic engineering, elucidation of molecular pathways, and understanding of disease mechanisms. The identification of interface residues can also guide the docking process to build the structural model of protein-protein complexes. This dissertation focuses on developing computational approaches for protein-ligand and protein-protein binding site prediction and applying these predictions to improve protein-protein docking. First, we develop an automated approach LIGSITEcs to predict protein-ligand binding site, based on the notion of surface-solvent-surface events and the degree of conservation of the involved surface residues. We compare our algorithm to four other approaches, LIGSITE, CAST, PASS, and SURFNET, and evaluate all on a dataset of 48 unbound/bound structures and 210 bound-structures. LIGSITEcs performs slightly better than the other tools and achieves a success rate of 71% and 75%, respectively. Second, for protein-protein binding site, we develop metaPPI, a meta server for interface prediction. MetaPPI combines results from a number of tools, such as PPI_Pred, PPISP, PINUP, Promate, and SPPIDER, which predict enzyme-inhibitor interfaces with success rates of 23% to 55% and other interfaces with 10% to 28% on a benchmark dataset of 62 complexes. After refinement, metaPPI significantly improves prediction success rates to 70% for enzyme-inhibitor and 44% for other interfaces. Third, for protein-protein docking, we develop a FFT-based docking algorithm and system BDOCK, which includes specific scoring functions for specific types of complexes. BDOCK uses family-based residue interface propensities as a scoring function and obtains improvement factors of 4-30 for enzyme-inhibitor and 4-11 for antibody-antigen complexes in two specific SCOP families. Furthermore, the degrees of buriedness of surface residues are integrated into BDOCK, which improves the shape discriminator for enzyme-inhibitor complexes. The predicted interfaces from metaPPI are integrated as well, either during docking or after docking. The evaluation results show that reliable interface predictions improve the discrimination between near-native solutions and false positive. Finally, we propose an implicit method to deal with the flexibility of proteins by softening the surface, to improve docking for non enzyme-inhibitor complexes.

Molecular recognition, defined as the specific interactions between two or more molecules, is at the center of many biological processes including catalysis, signal transduction, gene regulation and allostery. Allosteric regulation is the modification of function caused by an intermolecular interaction. Allosteric proteins modify their activity in response to a biological signal that is often transmitted through the interaction with a small effector molecule. Therefore, determination of the origins of intermolecular interactions involved in molecular recognition and allostery are essential for understanding biological processes. Classically, molecular recognition and allosteric regulation have been associated to structural changes of the system. NMR spectroscopic methods have indicated that changes in protein dynamics may also contribute to molecular recognition and allostery. This thesis is an investigation of the contributions of both structure and dynamics in molecular binding phenomena. In chapter I, I describe molecular recognition, allostery and examples of allostery and cooperativity. Then I discuss the contribution of protein dynamics to function with a special focus on allosteric regulation. Lastly I introduce the hemoglobin homodimer, HbI of Scapharca inaequivalvis and the mRNA binding protein TIS11d. Chapter II is the primary focus of this thesis on the contribution of protein dynamics to allostery in the dimeric hemoglobin of scapharca inaequivalvis, HbI. Thereafter I concentrate on the mechanism of adenine recognition of the Tristetraprolin-like (TTP) protein TIS11d; this study is detailed in Chapter III. In Chapter IV I discuss broader impacts and future directions of my research. This thesis presents an example of the use of protein NMR spectroscopy to probe ligand binding. The studies presented in this thesis emphasize the importance of dynamics in understanding protein function. Measurements of protein motions will be an element of future studies to understand protein function in health and disease.

Indiana University-Purdue University Indianapolis (IUPUI) / The discovery and isolation of naturally occurring fluorescent proteins, FPs, have provided much needed tools for molecular and cellular level studies. Specifically the cloning of green fluorescent protein, GFP, revolutionized the field of biotechnology and biochemical research. Recently, a red fluorescent protein, DsRed, isolated from the Discosoma coral has further expanded the pallet of available fluorescent tools. DsRed shares only 23 % amino acid sequence homology with GFP, however the X-ray crystal structures of the two proteins are nearly identical. DsRed has been subjected to a number of mutagenesis studies, which have been found to offer improved physical and spectral characteristics. One such mutant, DsRed-Monomer, with a total of 45 amino acid substitutions in native DsRed, has shown improved fluorescence characteristics without the toxic oligomerization seen for the native protein. In our laboratory, we have demonstrated that DsRed proteins have a unique and selective copper-binding affinity, which results in fluorescence quenching. This copper-binding property was utilized in the purification of DsRed proteins using copper-bound affinity columns. The work presented here has explored the mechanism of copper-binding by DsRed-Monomer using binding studies, molecular biology, and other biochemical techniques. Another focus of this thesis work was to demonstrate the applications of DsRed-Monomer in biochemical studies based on the copper-binding affinity and fluorescence properties of the protein. To achieve this, we have focused on genetic fusions of DsRed-Monomer with peptides and proteins. The work with these fusions have demonstrated the feasibility of using DsRed-Monomer as a dual functional tag, as both an affinity tag and as a label in the development of a fluorescence assay to detect a ligand of interest. Further, a complex between DsRed-Monomer-bait peptide/protein fusion and an interacting protein has been isolated taking advantage of the copper-binding affinity of DsRed-Monomer. We have also demonstrated the use of non-natural amino acid analogues, incorporated into the fluorophore of DsRed-Monomer, as a tool for varying the spectral properties of the protein. These mutations demonstrated not only shifted fluorescence emission compared to the native protein, but also improved extinction coefficients and quantum yields.

The study of pharmaceutical preformulation includes the evaluation of pharmacokinetic, pharmacodynamic and physicochemical properties of the drug molecules that aid the formulation. However, it has a limited role in determining drug dosage optimisation in the formulation. The study of drug-Plasma Protein Binding (PPB), and the lipophilicity, solubility, and ionic behaviours of the desired drug molecules addresses the gap and enhances our undertraining related to the behaviour of the drug molecules in the body. The High-Performance Liquid Chromatography (HPLC) technique was used in the current study to assess drug-PPB interaction. Using Michael Abraham’s ‘Linear Free Energy Relationship’ (LFER) method, two major plasma proteins namely, Human Serum Albumin as HSA and α-1-Acid Glycoprotein as AGP, were used and the structural properties governing drug-plasma protein binding was determined. This is the first time that the effect of ionised species on PPB has been quantitatively evaluated. In addition, the molecular interactions also play a key role in the supramolecular complexes of co-crystals. The project also evaluated the co-crystallisation process and its effect on physicochemical properties of the drug. In the current study, amino acids (AAs) have been observed to be a prominent source of coformers. The AAs showed co-crystals formation with carboxylic acids, nonsteroidal anti-inflammatory drug (NSAID) and citric acid which overcome the hygroscopicity problems and improved the physical stability issues during storage. This study has also identified a new formulation which is helpful for improvement in the stability of effervescent tablets at various relative humidity (RH) conditions which will reduce the manufacturing cost associated with the production of effervescent tablets.

Szeto Tsz Kwan Leo. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 112-120). / Abstracts in English and Chinese. / Abstract --- p.i / 摘要 --- p.iii / Acknowledgements --- p.v / Table of Contents --- p.vi / List of Tables --- p.ix / List of Figures --- p.x / Abbreviations --- p.xii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Heavy metals contaminations in Shing Mun River --- p.1 / Chapter 1.1 --- Importance of copper regulation and role of liverin copper metabolism --- p.6 / Chapter 1.1.1 --- Role of copper --- p.6 / Chapter 1.1.2 --- Toxicity due to unbalanced copper regulation --- p.7 / Chapter 1.1.3 --- Function of liver in copper detoxification --- p.9 / Chapter 1.2 --- Aims and rationale of this research --- p.11 / Chapter Chapter 2 --- Heavy metal concentrations of tilapia samples collected from Shing Mun River --- p.12 / Chapter 2.1 --- Introduction --- p.12 / Chapter 2.1.1 --- Sampling sites - Fo Tan and Siu Lek Yuen Nullah --- p.12 / Chapter 2.1.2 --- Tilapia samples collected from the sites --- p.16 / Chapter 2.1.3 --- Tilapia as a study model --- p.18 / Chapter 2.1.4 --- Bioavailability of heavy metals in water --- p.19 / Chapter 2.1.5 --- Metal content in liver --- p.20 / Chapter 2.1.6 --- Aim of this chapter --- p.20 / Chapter 2.2 --- Materials and Methods --- p.22 / Chapter 2.2.1 --- Collection of control and field samples --- p.22 / Chapter 2.2.2 --- Heavy metal concentrations determination --- p.23 / Chapter 2.2.3 --- Homogenization of liver cells --- p.24 / Chapter 2.2.4 --- Subcellular fractionation --- p.24 / Chapter 2.2.5 --- Determination of copper and zinc content in each subcellular fraction --- p.253 / Chapter 2.3 --- Results --- p.27 / Chapter 2.3.1 --- Physical data --- p.27 / Chapter 2.3.2 --- Metal concentrations in liver and muscle --- p.27 / Chapter 2.3.3 --- Copper and zinc subcellular distribution in liver cell --- p.33 / Chapter 2.4 --- Discussion --- p.36 / Chapter 2.4.1 --- Difference in metal concentration between sites --- p.36 / Chapter 2.4.2 --- Copper contamination in water and fish organ (muscle and liver) from the Shing Mun River --- p.36 / Chapter 2.4.3 --- Comparison of metal content in muscle and liver at Fo Tan site with previous studies --- p.39 / Chapter 2.4.4 --- Copper and zinc concentrations in the liver of tilapia --- p.42 / Chapter 2.4.5 --- Copper and zinc sebcellular distribution in the liver of tilapia --- p.43 / Chapter Chapter 3 --- Column chromatography of hepatic proteins from tilapias --- p.44 / Chapter 3.1 --- Transport of metals from circulatory system to liver --- p.44 / Chapter 3.1.1 --- Copper transporting plasma proteins in vertebrates --- p.44 / Chapter 3.1.2 --- Copper uptake into hepatocytes --- p.45 / Chapter 3.1.3 --- Intracellular metabolism of copper --- p.48 / Chapter 3.1.4 --- Mechanism of copper toxicity following excess accumulation --- p.49 / Chapter 3.1.5 --- Aim of this chapter --- p.50 / Chapter 3.2 --- Materials and Methods --- p.51 / Chapter 3.2.1 --- Purification of liver cytosolic proteins by gel-filtration column chromatography --- p.51 / Chapter 3.2.2 --- Copper content detection in elution --- p.52 / Chapter 3.2.3 --- Analysis of peaks from elution profile using tricine gel SDS PAGE --- p.53 / Chapter 3.3 --- Results --- p.55 / Chapter 3.3.1 --- Gel-filtration liquid chromatography elution profiles --- p.55 / Chapter 3.3.2 --- SDS PAGE analysis of peaks in elution profiles --- p.51 / Chapter 3.4 --- Discussion --- p.54 / Chapter 3.4.1 --- Comparison of gel filtration profiles of sample liver cytosol between sites and sexes --- p.64 / Chapter 3.4.2 --- Possible proteins in peaks found in the gel filtration profiles --- p.64 / Chapter 3.4.3 --- Common copper-indeced proteins --- p.67 / Chapter 3.5 --- Conclusion --- p.70 / Chapter Chapter 4 --- Two-dimensional electrophoresis of hepatic cutosol of tilapias caught from Shing Mun River and copper-treated HEPA T1 cell --- p.72 / Chapter 4.1 --- Introduction --- p.72 / Chapter 4.1.1 --- The need of ´بin vitro' experiment --- p.72 / Chapter 4.1.2 --- Choice of cell line --- p.73 / Chapter 4.1.3 --- Aim of this chapter --- p.74 / Chapter 4.2 --- Materials and Methods --- p.76 / Chapter 4.2.1 --- HEPA T1 cell cultivation --- p.76 / Chapter 4.2.2 --- Copper exposure of HEPA T1 cell --- p.77 / Chapter 4.2.3 --- Subcellular protein extraction of the copper-treated HEPA T1 cells --- p.77 / Chapter 4.2.4 --- Bicinchoninic Acidic (BCA) Protein Assay --- p.79 / Chapter 4.2.5 --- Two-dimensional gel electrophoresis --- p.79 / Chapter 4.3 --- Results --- p.83 / Chapter 4.3.1 --- Graphical presentation of spots observed on 2-dimensional gel of field samples and copper-injected samples --- p.33 / Chapter 4.3.2 --- Graphical presentation of spots detected on 2-dimensional gel of HEPAT1 cells --- p.84 / Chapter 4.3.3 --- Comparison of matched spots on 2-dimensional gels among control and copper-treated HEPAT1 cells --- p.97 / Chapter 4.4 --- Discussion --- p.105 / Chapter 4.4.1 --- Comparison of the spot patterns between field sample and copperOtreated HEPA T1 cells --- p.105 / Chapter 4.5 --- Conclusion --- p.107 / Chapter Chapter 5 --- General Discussions --- p.108 / Chapter 5.2 --- Research Overview --- p.108 / Chapter 5.2 --- Characterization of metal binding proteins from the cytosol of liver of tilapia --- p.109 / REFERENCES --- p.112

Στην παρούσα διπλωματική εργασία γίνεται χρήση λεπτών υμενίων TiO2 ως στερεό υπόστρωμα για την ακινητοποίηση πρωτεϊνών με απώτερο σκοπό την ανάπτυξη ενός αμπερομετρικού βιοαισθητήρα με ευαισθησία στο υπεροξείδιο του υδρογόνου (H2O2). Αρχικά περιγράφεται η λειτουργία των βιοαισθητήρων καθώς και οι σημαντικότεροι τύποι βιοαισθητήρων που έχουν κατασκευαστεί μέχρι σήμερα. Σημαντικό ρόλο στην επιτυχή κατασκευή ενός βιοαισθητήρα παίζει η επιλογή του υλικού που θα χρησιμοποιηθεί ως υπόστρωμα / ηλεκτρόδιο (υμένια TiO2) καθώς και ο τρόπος που ακινητοποιείται το βιομόριο πάνω σε αυτό, γι’ αυτό και έχει δοθεί έμφαση στην ανάλυση των παραπάνω πληροφοριών. Επίσης περιγράφεται η δομή και η φυσική λειτουργία της πρωτεΐνης, (κυτόχρωμα c), που χρησιμοποιήθηκε ως το βιομόριο επιλογής για την ανάπτυξη του βιοαισθητήρα. Αναλύθηκαν επίσης οι κρυσταλλικές δομές του διοξειδίου του τιτανίου, οι βασικές φυσικοχημικές τους ιδιότητες και οι λόγοι που επιλέξαμε την ανατάση για τη συγκεκριμένη εργασία. Περιγράφεται η πειραματική διαδικασία εναπόθεσης των υμενίων του TiO2 σε υποστρώματα αγώγιμου υάλου. Στη συνέχεια περιγράφονται οι πειραματικές διατάξεις που χρησιμοποιήθηκαν τόσο για τον χαρακτηρισμό των υμενίων διοξειδίου του τιτανίου (TiO2) όσο και για την αναλυτική μελέτη της ακινητοποίησης του κυτοχρώματος c πάνω σε αυτά. Τέλος περιγράφεται η ηλεκτροχημική κυψελίδα 3 ηλεκτροδίων και η τεχνική της κυκλικής βολταμετρίας που επιλέχθηκαν τόσο για τη μελέτη των ηλεκτροχημικών ιδιοτήτων των υμενίων TiO2 με ή χωρίς ακινητοποιημένη πρωτεΐνη όσο και για την ανάπτυξη ενός αμπερομετρικού βιοαισθητήρα με ευαισθησία στο H2O2. / In the present study, the use of thin nanocrystalline TiO2 films as solid substrates for protein immobilization and for the development of an electrochemical biosensor for hydrogen peroxide (H2O2) are investigated. First of all, a general description of biosensors and their most important types that have been developed to date is given. For the successful development of a biosensor, the choice of material/substrate used as the surface/electrode (thin film of TiO2) for the attachment of the bio-molecule of interest, as well as the manner in which the bio-molecule is immobilized upon it are critical and therefore emphasis is given for the analysis of this information. Furthermore, a description of the structure and basic functions of the bio-molecules (cytochrome c and hemoglobin), used for the immobilization studies and for the development of the biosensor is presented. Additionally, the crystalline structures of titanium dioxide have been analyzed, along with its basic physicochemical properties and the reasons for choosing its anatase structure for the specific project. In the experimental part, the deposition of the colloidal TiO2 paste on conducting glass for the preparation of the thin mesoporous TiO2 films is described in detail. Also described are the experimental techniques used for the characterization of these films as well as a thorough analysis of the binding of cytochrome c upon them and the parameters that influence its adsorption. Finally, description of the 3-elecrode electrochemical cell used in this study of perform of cyclic voltammetry experiments in order to investigate the electrochemical properties of the TiO2 thin films with or without immobilized protein is given. The same setup is also used for the development of an electrochemical biosensor for H2O2.